News
Find the latest news about Inaphaea BioLabs here
-
Meet the Inaphaea BioLabs team: Dr Dominic Lowen, Senior Scientist
In the third instalment of our ‘meet the team’ series for Inaphaea BioLabs, we discover a little more about Dominic Lowen.
-
Meet the Inaphaea BioLabs team: Melissa Barr, Lead Scientist
In the second instalment of our ‘meet the team’ series for Inaphaea BioLabs, we discover a little more about Melissa Barr.
-
Inaphaea BioLabs enters into agreement with OncoBone
Inaphaea BioLabs has entered into an agreement with virtual CRO services company, OncoBone Limited.
-
Imagen Therapeutics’ scientific assets to be transferred to Inaphaea BioLabs
ValiRx PLC, parent company of Inaphaea BioLabs, has announced the acquisition of the scientific assets of Imagen Therapeutics Limited.
-
Our services: immunoassays
Inaphaea are experts in developing immunoassays based on hormones and cytokines at our labs in MediCity, Nottingham as we strive to find new therapies in women’s health. In addition to our pre-validated…
-
Our services: cell cancer assays
At our Inaphaea labs in MediCity, Nottingham we provide a comprehensive range of validated assays such as cell cancer assays or can provide assay development and validation for your bespoke assay as…
-
2023 events round-up: ValiRx and Inaphaea BioLabs
2023 is proving to be a busy year for ValiRx and Inaphaea, and our events schedule is no different, with the team attending events up and down the country to meet potential…
-
Meet the Inaphaea BioLabs team: Dr Andrew Carnegie
In our first ‘Meet the Team’ instalment, we sit down with Dr Andrew Carnegie to discuss his experience and his role at Inaphaea. Read more here.
-
Inaphaea BioLabs and Physiomics join forces
Inaphaea BioLabs, a subsidiary of ValiRx PLC, is delighted to be entering into a collaborative services agreement with Physiomics PLC.
-
BioTrinity 2023
We are pleased to announce that the Inaphaea team will be attending BioTrinity in London on April 25-26 2023. BioTrinity is an established conference that catalyses growth and supports in-person engagement across…